These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 20002666

  • 41. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.
    J Clin Oncol; 2009 Jun 20; 27(18):2924-30. PubMed ID: 19433689
    [Abstract] [Full Text] [Related]

  • 42. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S, Madsen M, Palmqvist E, Mäkelä E, Klintenberg C, Aus G.
    Scand J Urol Nephrol; 2009 Jun 20; 43(3):186-91. PubMed ID: 19353383
    [Abstract] [Full Text] [Related]

  • 43. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.
    Can J Urol; 2009 Oct 20; 16(5):4813-9. PubMed ID: 19796456
    [Abstract] [Full Text] [Related]

  • 44. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
    Cancer; 2008 Mar 15; 112(6):1247-53. PubMed ID: 18293426
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.
    Urol Oncol; 2012 Sep 15; 30(5):577-83. PubMed ID: 21292508
    [Abstract] [Full Text] [Related]

  • 48. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC.
    J Urol; 2009 Aug 15; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 52. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 53. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A.
    BJU Int; 2007 Jan 15; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [Abstract] [Full Text] [Related]

  • 54. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 15; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S, You D, Kim YS, Hong JH, Ahn H, Kim CS.
    Urol Int; 2017 Aug 15; 99(4):406-413. PubMed ID: 29020683
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2013 Mar 01; 85(3):693-9. PubMed ID: 22836052
    [Abstract] [Full Text] [Related]

  • 59. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment.
    Miocinovic R, Berglund RK, Stephenson AJ, Jones JS, Fergany A, Kaouk J, Klein EA.
    Urology; 2011 Apr 01; 77(4):946-50. PubMed ID: 21477723
    [Abstract] [Full Text] [Related]

  • 60. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e335-44. PubMed ID: 21645976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.